SEC Form 4 · accession 0001179110-17-008829
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Stephen R Fussell
Officer — Executive Vice President
Period of report
Jun 8, 2017
Accepted (ET)
Jun 9, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par value | Jun 8, 2017 | M | 39,350 | $26.6973 | A | 221,488 | D | |
| Common shares without par value | Jun 8, 2017 | M | 38,700 | $26.015 | A | 260,188 | D | |
| Common shares without par value | Jun 8, 2017 | M | 28,700 | $26.1879 | A | 288,888 | D | |
| Common shares without par value | Jun 8, 2017 | M | 45,800 | $22.3919 | A | 334,688 | D | |
| Common shares without par value | Jun 8, 2017 | M | 44,000 | $27.0336 | A | 378,688 | D | |
| Common shares without par value | Jun 8, 2017 | S | 50 | $46.931 | D | 378,638 | D | |
| Common shares without par value | Jun 8, 2017 | S | 500 | $46.02 | D | 378,138 | D | |
| Common shares without par value | Jun 8, 2017 | S | 300 | $46.01 | D | 377,838 | D | |
| Common shares without par value | Jun 8, 2017 | S | 195,700 | $46.00 | D | 182,138 | D | |
| Common shares without par valueF1 | holding | — | — | — | 1,561 | I | Profit Sharing Trust | |
| Common shares without par valueF2 | holding | — | — | — | 53 | I | By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F3 | $26.6973 | Jun 8, 2017 | M | 39,350 | D | Feb 15, 2011 | Feb 14, 2018 | Common shares | 39,350 | 0 | D |
| Option (right to buy)F3 | $26.015 | Jun 8, 2017 | M | 38,700 | D | Feb 20, 2012 | Feb 19, 2019 | Common shares | 38,700 | 0 | D |
| Option (right to buy)F4 | $26.1879 | Jun 8, 2017 | M | 28,700 | D | Feb 19, 2013 | Feb 18, 2020 | Common shares | 28,700 | 0 | D |
| Option (right to buy)F4 | $22.3919 | Jun 8, 2017 | M | 45,800 | D | Feb 18, 2014 | Feb 17, 2021 | Common shares | 45,800 | 0 | D |
| Option (right to buy)F4 | $27.0336 | Jun 8, 2017 | M | 44,000 | D | Feb 17, 2015 | Feb 16, 2022 | Common shares | 44,000 | 0 | D |
Explanation of responses
- F1Balance in the Abbott Laboratories Stock Retirement Trust as of June 8, 2017.
- F2The reporting person disclaims beneficial ownership of all securities held by his spouse.
- F3Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
- F4Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Remarks
These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).